ERBB2 and breast carcinoma: Compared with peptides, the antibodies, ankyrin repeat proteins that target HER2 fused with LAMP-2B exhibit higher binding affinities toward receptors on HER2-positive breast cancers cells, showing a four-fold uptake of engineered EVs in vitro [135].